Találati lista | Tudóstér

001-es BibID:	BIBFORM106172
035-os BibID:	(scopus)85145670780 (wos)000909053600001
Első szerző:	Galgóczi Erika (biológus)
Cím:	Glucocorticoids Directly Affect Hyaluronan Production of Orbital Fibroblasts : a Potential Pleiotropic Effect in Graves' Orbitopathy / Galgoczi Erika, Katko Monika, Papp Fruzsina Reka, Csiki Robert, Csiha Sara, Erdei Annamaria, Bodor Miklos, Ujhelyi Bernadett, Steiber Zita, Gyory Ferenc, Nagy Endre V.
Dátum:	2022
ISSN:	1420-3049
Megjegyzések:	Orbital connective tissue expansion is a hallmark of Graves' orbitopathy (GO). In moderateto-severe active GO, glucocorticoids (GC) are the first line of treatment. Here we show that hydrocortisone (HC), prednisolone (P), methylprednisolone (MP), and dexamethasone (DEX) inhibit the hyaluronan (HA) production of orbital (OF) and dermal (DF) fibroblasts. HA production of GO OFs (n = 4), NON-GO OFs (n = 4) and DFs (n = 4) was measured by ELISA. mRNA expression of enzymes of HA metabolism and fibroblast proliferation was examined by RT-PCR and BrdU incorporation, respectively. After 24 h of GC treatment (1?M) HA production decreased by an average of 67.9 ? 3.11% (p < 0.0001) in all cell cultures. HAS2, HAS3 and HYAL1 expression in OFs also decreased (p = 0.009, p = 0.0005 and p = 0.015, respectively). Ten ng/mL PDGF-BB increased HA production and fibroblast proliferation in all cell lines (p < 0.0001); GC treatment remained effective and reduced HA production under PDGF-BB-stimulated conditions (p < 0.0001). MP and DEX reduced (p < 0.001, p = 0.002, respectively) PDGF-BB-induced HAS2 expression in OFs. MP and DEX treatment decreased PDGF-BB stimulated HAS3 expression (p = 0.035 and p = 0.029, respectively). None of the GCs tested reduced the PDGF-BB stimulated proliferation rate. Our results confirm that GCs directly reduce the HA production of OFs, which may contribute to the beneficial effect of GCs in GO.
Tárgyszavak:	Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Graves' orbitopathy hyaluronan glucocorticoids hyaluronan synthase methylprednisolone prednisolone hydrocortisone dexamethasone
Megjelenés:	Molecules. - 28 : 1 (2022), p. 1-12. -
További szerzők:	Katkó Mónika (1980-) (biológus) Papp Fruzsina Réka (1995-) (klinikai laboratóriumi kutató) Csiki Róbert (1997-) (gyógyszerész) Csiha Sára (1985-) (Biológus) Erdei Annamária (1976-) (belgyógyász) Bodor Miklós (1969-) (belgyógyász, endokrinológus) Ujhelyi Bernadett (1981-) (szemész) Steiber Zita (1977-) (orvos, szemész) Győry Ferenc (1964-) (sebész) Nagy Endre V. (1957-) (belgyógyász, endokrinológus)
Pályázati támogatás:	OTKA-K143464 OTKA
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM133290
Első szerző:	Ratku Balázs (mentőtiszt)
Cím:	Alterations of lipoprotein subfractions in GH-deficient adults / Balázs Ratku, Hajnalka Lőrincz, Sára Csiha, Lajos Bíró, Annamária Erdei, Eszter Berta, Dóra Ujvárosy, Miklós Bodor, Endre V. Nagy, Zoltán Szabó, Mariann Harangi, Sándor Somodi
Dátum:	2025
ISSN:	1664-2392
Megjegyzések:	Introduction: Dyslipidemia is a common complication of adult growth hormone de ciency (AGHD) and considered an important contributor to increased mortality. Previous studies mainly focused on quantitative assessment of lipoproteins, but lipoprotein subfractions and their relationship with insulin-like growth factor 1 (IGF-1) have not been explored. Purpose: To perform a comprehensive evaluation of lipoprotein subfractions and measuring apolipoprotein L1 (apoL1), sphingosine 1-phosphate (S1P) and apolipoprotein M (apoM) in AGHD. Materials and methods: 11 GH-substituted (GHS) patients, 9 GH-unsubstituted (GHU) patients and 37 controls were included in the study. Lipoprotein subfractions were separated by the Lipoprint system. ApoL1, apoM and S1P were determined by ELISA. In the GHS patients GH-replacement was discontinued for 2 months. Measurements were performed before GH- discontinuation, at the end of the 2-month GH-withdrawal, and 1 month after reinstituting GH-replacement. Results: Standard lipid parameters, apoM and apoL levels were not different between the groups. GHU patients demonstrated lower apolipoprotein A1 compared to controls (p=0.02) and higher apolipoprotein B100 compared to GHS (p=0.02). GHU and GHS showed higher S1P levels compared to controls (p=0.04 and p=0.01, respectively). Both GHU and GHS patients also presented higher percentage of intermediate-density lipoprotein (IDL) compared to controls (p=0.03 and p=0.01, respectively). Mean LDL size was lower in GHU compared to GHS (p=0.04). Percentage of intermediate HDL was lower in GHU and GHS compared to controls (p<0.001 and p<0.01, respectively). GHU demonstrated higher percentage of small HDL than controls (p<0.001). Overall, log10IGF-1 correlated positively with the percentage of large HDL (r=0.27; p=0.04) and intermediate HDL (r=0.38; p<0.01) and negatively with the percentage of small HDL (r=-0.46; p<0.01). Log10IGF-1 was the best predictor of small HDL (standardized b=-0.46; p<0.001) in overall subjects. In the GH-withdrawal study, the amount of HDL-6 increased with GH-withdrawal (p=0.03) and the percentage of IDL increased with reinstitution (p=0.05). Conclusion: Despite no changes in standard lipid parameters, considerable alterations of lipoprotein subfractions were revealed in GH-de cient adults indicating that lipoprotein subfraction analysis may allow for a more precise cardiovascular risk assessment in AGHD. Associations between HDL subfractions and Log10IGF-1 demonstrate a novel insight into the role of GH in lipid metabolism.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk adult growth hormone de ciency dyslipidemia high-density lipoprotein ipoprotein subfractions sphingosine 1-phosphate insulin-like growth factor 1
Megjelenés:	Frontiers in Endocrinology. - 16 (2025), p. 1-14. -
További szerzők:	Lőrincz Hajnalka (1986-) (biológus) Csiha Sára (1985-) (Biológus) Biró Lajos Erdei Annamária (1976-) (belgyógyász) Berta Eszter (1980-) (belgyógyász) Ujvárosy Dóra (1985-) Bodor Miklós (1969-) (belgyógyász, endokrinológus) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Szabó Zoltán (1973-) (belgyógyász, kardiológus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Somodi Sándor (1977-) (belgyógyász)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: